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Abstract Glycogen storage disease (GSD) 1b is the deficiency
of endoplasmic reticulum glucose-6-phosphate (G6P) transport.
We here report the structure of the gene encoding a protein likely
to be responsible for G6P transport, and its mapping to human
chromosome 11q23.3. The gene is composed of nine exons
spanning a genomic region of approximately 4 kb. Primers based
on the genomic sequence were used in single strand conformation
polymorphism (SSCP) analysis and mutations were found in six
out of seven GSD 1b patients analysed.
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1. Introduction
Glycogen storage disease type 1 (GSD 1), also known as
‘von Gierke disease’, is an autosomal recessive disorder due to
a de¢ciency of glucose-6-phosphatase activity (G6Pase; EC
3.1.3.9) [1,2]. This enzyme catalyses the terminal reaction of
glycogenolysis and gluconeogenesis and plays a key role in the
maintenance of blood glucose homeostasis [3,4]. G6Pase is
mainly represented in liver and kidney where the catalytic
subunit is localised in the lumen of the endoplasmic reticulum
(ER). According to the ‘substrate-transport’ model [1,5^7], at
least three transport systems are necessary to allow its activity.
It has been proposed that the enzyme utilises one transport
system (G6PT1) to translocate glucose-6-phosphate (G6P)
from the cytosol to the lumen of the ER and two other trans-
port systems to transport the reaction products phosphate (Pi)
and glucose (G6PT2 and G6PT3 respectively) to the cytosol
[8]. The liver G6PT1 transport protein(s) have not yet been
identi¢ed. However G6P uptake into liver microsomal vesicles
has been clearly demonstrated [9]. All the components of the
G6Pase system can be absent or altered in the GSD 1 leading
to di¡erent subtypes of GSD 1 [1]. GSD type 1a is due to a
de¢ciency of the catalytic subunit (G6PC), whereas 1b, 1c and
1d forms are the consequence of a de¢cit in the transport of
G6P, Pi and glucose respectively. All GSD subtypes show the
same clinical pro¢le with the exception of GSD 1b that usu-
ally shows, in addition to hypoglycemia and hepatomegaly,
neutropenia and impaired neutrophil function and is, there-
fore, the most severe form [1]. Alterations of the gene coding
for G6PC are responsible for type 1a GSD and several muta-
tions abolishing or greatly reducing enzyme activity have been
described [10^12]. No mutations in the G6PC gene have been
found in patients with GSD 1b who are de¢cient in liver
microsomal G6P transport [13], thus con¢rming that an addi-
tional protein(s) is necessary for ER G6P transport [10].
Recently, a human liver EST cDNA sequence has been
identi¢ed on the basis of its homology with the coding se-
quence of bacterial transporters for phosphate esters [14].
The EST was most like UhpC (G6P receptor of Escherichia
coli), a membrane protein involved in the regulation of UhpT
(hexose-6-phosphate transporter of E. coli) [15]. The corre-
sponding full length cDNA sequence was found to be mutated
in two GSD 1b patients and therefore it is a logic candidate
for encoding the putative G6P translocase, or a protein in-
volved in the regulation of the translocase itself [14]. A splic-
ing variant of this cDNA, containing an additional 66 bp, has
been identi¢ed in brain RNA [16].
Here we describe the characterisation of the putative G6P
translocase gene and its involvement in GSD 1b. The genomic
region containing the gene has been cloned and all exons and
intron-exon boundaries have been sequenced. The gene con-
tains nine exons and has been localised by in situ hybridisa-
tion technique to chromosome 11q23.3. Single strand confor-
mational polymorphism (SSCP) analysis revealed that this
locus is mutated in six out of seven GSD 1b patients.
2. Materials and methods
2.1. Patients
All the seven GSD 1b patients analysed (¢ve from Italy, one from
PeruØ and one from Australia) showed, in addition to the typical clin-
ical symptoms of GSD 1, neutropenia and impaired neutrophil func-
tion, and ¢ve of them were initially diagnosed by kinetic analysis of
G6Pase system activity in liver biopsy samples (see Table 3). Genomic
DNA was isolated from peripheral blood of patients (and their avail-
able relatives).
2.2. Methods
Exon-intron structure of the G6P translocase gene was obtained by
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a PCR based method. Human genomic DNA was PCR ampli¢ed with
Taq polymerase using the following couples of primers designed on
the basis of the putative G6P translocase cDNA sequence [14]:
G6PT129F (5P-AGGCTGTGCGTCTTGGCTGGTAGGG-3P) and
G6PT530R (5P-ACCACTTCCGCAGGACCTTCCCACA-3P) ;
G6PT530F (5P-TGTGGGAAGGTCCTGCGGAAGTGGT-3P) and
G6PT834R (5P-GAGAGCACCCACAGGTAAGGGGACA-3P) ;
G6PT834F (5P-TGTCCCCTTACCTGTGGGTGCTCTC-3P) and
G6PT1161R (5P-CCAAATACAGCTCCCAATACCAGGA-3P) ;
G6PT1161F (5P-TCCTGGTATTGGGAGCTGTATTTGG-3P) and
G6PT1490R (5P-AGAGCGTGCAGGGGGAAGGCCACCG-3P).
Brie£y, PCR reactions were set up in a total volume of 100 Wl con-
taining 300^500 ng of genomic DNA, 50 pmol of each oligonucleotide
primer, 200 WM of each dNTP, 1.5 mM MgCl2, 10 mM Tris (pH 8.3),
50 mM KCl and 2.5 U Taq polymerase. Thirty-¢ve cycles of ampli-
¢cation were performed in each case at 94‡C for 1 min, at the anneal-
ing temperature (60‡C) for 1 min and at 72‡C for 1 min. A ¢nal
elongation step of 72‡C for 4 min was also carried out.
The PCR products were cloned in the p-GEM-T Easy plasmid
(Promega) and subsequently sequenced by the dideoxy chain termina-
tion method using the Sequenase 2.0 kit (USB).
FISH was performed as previously described [18] using as hybrid-
isation probe the full length G6P translocase cDNA obtained by RT-
PCR. The probe was labelled by nick translation with biotin-16-dUTP
(Boehringer Mannheim) according to the manufacturer’s protocol.
Hybridisation was performed on lymphocyte metaphases. Chromo-
somes were counterstained with propidium iodide 1 Wg/ml and banded
with diaminophenylnindole (DAPI). Only those chromosomes with
signals present on both chromatids at the same band position were
taken into consideration. Among 48 well-spread metaphases, 25
showed signals at 11q23.3. No other clusters of signals were found.
For the SSCP analysis [19] PCR primers were designed on the
intronic sequences £anking each exon in order to be able to detect
mutations both in the coding region and in the splicing consensus
sequence.
Primer sequence and PCR conditions used for SSCP analysis are
reported in Table 1 together with the expected size of the ampli¢ed
fragments.
Di¡erent gel compositions were applied for each exon in order to
increase the probability of detecting SSCP variant bands [20,21]. In
particular 4^8 Wl of PCR product were loaded on non-denaturing
polyacrylamide gel containing 6% acrylamide prepared with a 99:1
ratio between acrylamide and bis-acrylamide and alternatively with or
without 5% glycerol in 0.5UTBE. Gels were run in a cold room for 1^
4 h at 30 W. DNA bands on the gel were visualised by silver staining.
After SSCP analysis, each sample showing a conformational variant
was sequenced using the Sequenase 2.0 kit (USB) directly from the
puri¢ed PCR product. Once a mutation had been detected in any of
these patients, all the available relatives were analysed.
G6Pase assays (with a range of G6P and pyrophosphate concen-
trations) and glycogen content analysis were carried out on micro-
somes isolated from the biopsy sample from patient C32 (see Table
3) as described in [22,23]. The biopsy samples from patients 3, 7, 10,
and 14 (see Table 3) were split into two. One portion was immediately
homogenised in 1% wet weight 0.25 M sucrose, the other was frozen
with dry ice and then thawed and homogenised in distilled water 1%
wet weight. Both were centrifuged at 500Ug for 5 min. Supernatants
were used for assays. Both were diluted 1 to 1 in 0.1 M G6P, 2 mM
EDTA pH 6.5 for assay of phosphate released [24]. In addition 5 Wl of
0.1 M acetate pH 5.0 was added to 50 Wl of both supernatants which
were then incubated to inactive speci¢c G6Pase activity [25]. These
samples were then diluted in 0.1 M G6P, 2 mM EDTA as above and
assayed at pH 6.5 to obtain a value for non-speci¢c phosphatase
activity. All the enzyme activity values in Table 3 have been corrected
for non-speci¢c phosphatase activity.
3. Results
The human genomic region covering the putative G6P
translocase gene was PCR ampli¢ed with four couples of
primers designed on sequence of the putative G6P translocase
cDNA. Four fragments spanning the total length of this gene
were cloned and sequenced. The genomic structure of the G6P
translocase is shown in Table 2. The gene spans a genomic
region of approximately 4 kb and consists of nine exons. In-
tron size range from 113 bp to V560 bp. All intron-exon
boundaries were sequenced and conformed to the GT/AG
rule [26]. By FISH (see Section 2 for details) we have physi-
cally mapped the putative human G6P translocase gene to
chromosome 11q23.3.
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Table 1
Primers and PCR conditions used for the ampli¢cation of the nine exons
Exon PCR product
size (bp)
Annealing temperature
(‡C)
MgCl2
(mM)
Forward primer (5PC3P) Reverse primer (5PC3P)
1 232 60 1.5 AGGCTGTGCGTCTTGGCTGGTAGGG TTCTGTGTCCCCAGGTCCACCA
2 340 52 1.5 CCTTCTTTCATTGCTCCTGTGTTT CTCTATGACAATCCAAACAGGCTC
3 340 66 1.5 CTGCCCCATCTGACCCCACCCTCA AGTGGTCGGTCTGGGTGGGGGCTC
4 249 66 1.5 GGGGAGAGCAGTCAGGCAGAGCCT CTGCTCCTTATGCCCACCCTTGTC
5 150 62 1.5 TCCCTCTTCCCACCACAACTCCCT CCCTTCTCCTTCCTGTCCCTTCTG
6 191 62 1.2 TGTTCTGAGGACGTGACATTGCCG CCTTGTGCCCTGCCGTGAGCC
7 168 60 1.5 TCTGGGCCTGGTTTTCTTTTCTTC GTGAGACAGACCAGGAGAAAAACC
8 212 60 1.5 CTCTGAATGCCACTCCACTCTCCC ACAGGTGGGGGTGAGGGAGAGACT
9 250 60 1.5 GCTTAGGTTCTTCCCTTTCCCCTG AGAGCGTGCAGGGGGAAGGCCACCG
Table 2
Genomic structure of the human glucose-6-phosphate translocase gene
Exon size (bp) Intron size (bp) 5P Splice site 3P Splice site
1 317 w560 TGGgtgagccctg ttccctgcagGGT
2 233 s 275 AAGgtggtgagtg tgccccacagTGG
3 244 s 358 AGGgtgagccccc ccacctccagGCT
4 159 s 185 TAGgtaagatgag cctactgcagGTA
5 86 s 265 AAGgtgagcgggc gtatccatagGCG
6 114 w210 AAGgtaattaaga gctcctctagGAT
7 66 w182 GAGgtgccttaaa cccttggcagCTC
8 139 113 ATGgtaagtgtta cccctgacagTGG
9 729
Exon 1 and exon 9 contain 169 and 572 nucleotides of 5P and 3P untranslated region respectively. Exon sequences are in upper case letters and
intron sequences are in lower case letters.
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Starting from the genomic sequence obtained, we designed
primers in the intronic sequences £anking each exon in order
to be able to amplify the coding region and the splicing con-
sensus sequence of these exons. Using these sets of primers it
was possible to obtain a unique SSCP pattern for each exon
analysed. SSCP band shifts were observed in three exons in
the GSD 1b patients analysed. The altered exons in which an
SSCP variant was observed were ampli¢ed again from ge-
nomic DNA and directly sequenced.
Table 3 summarises the G6Pase activity measured in the
liver biopsy samples from ¢ve out of the seven GSD 1b pa-
tients here investigated. In all cases where the G6Pase activity
was measured, it was normal under experimental conditions
suitable to disrupt ER membrane integrity (i.e. when the
transport proteins are not rate limiting) demonstrating that
the G6PC was functioning normally and ruling out GSD
type 1a. In contrast, in all untreated preparations the activity
with G6P as substrate was either absent or very low (mean
latency at Vmax was 92%) indicating a G6P transport protein
defect. In patient C32, G6PC activity was also measured with
pyrophosphate as substrate; the individual values were all
within the normal range in both disrupted microsomes,
Vmax = 0.4 Wmoles/min/mg microsomal protein, Km = 0.8 mM
(control human liver values n = 25, Vmax = 0.2 þ 0.02 Wmoles/
min/mg microsomal protein, Km = 0.7 þ 0.1 mM) and intact
microsomes, Vmax = 0.1 Wmoles/min/mg microsomal protein,
Km = 4 mM (control human liver values n = 25,
Vmax = 0.1 þ 0.01 Wmoles/min/mg microsomal protein,
Km = 2.5 þ 0.3 mM) although the latency with pyrophosphate
as substrate was somewhat higher than normal (75%).
SSCP analysis of the coding sequence and exon-intron
boundaries of the human G6P translocase gene in these
GSD 1b patients resulted in the detection of ¢ve novel muta-
tions. Table 3 summarises the mutations identi¢ed which in-
clude one missense mutation, one possible splicing alteration
and three frameshifts. In particular, we found a GCA tran-
sition at nucleotide 1068 causing a non-conservative amino
acid substitution in patient 18 and in his carrier mother. A
three base deletion in the donor splicing site of intron 2 has
been found in patient 10 and in her carrier parents. This
mutation is likely to determine a splicing error between exons
2 and 3, even though no direct proof has been obtained since
mRNA from this patient was not available. The remaining
mutations involved the deletion of one or two nucleotides
causing a frameshift in the coding sequence. The deletion of
the guanosine in position 350, found in the homozygous state
in patient 15 (parents are not available), resulted in a stop
codon after the ¢rst 94 amino acids. Another deletion
(1094delG) was detected, together with the G1068A mutation,
in patient 18 and in his carrier father. Two nucleotides (1211^
1212delCT) were deleted in patient 3 and in his carrier pa-
rents. The same mutation was found in one allele of patient 7
and patient C32. This mutated allele was inherited in patient 7
from the mother and in patient C32 from the father. Although
all the patients were screened by SSCP for all the exons, no
additional mutations were found in the patients carrying the
above described mutations.
4. Discussion
GSD 1b is an autosomal recessive disorder caused by a
defect in the transport of G6P across the liver ER membrane.
The existence of a G6P translocase has been demonstrated
biochemically in liver microsomal vesicles [9]. Consistently,
G6P transport has been shown to be de¢cient in one GSD
1b case [27]. More recently, the cDNA of a putative human
G6P translocase has been identi¢ed and found mutated in two
GSD 1b patients [14].
In this paper, we describe the structure and the chromoso-
mal localisation of the gene coding for the translocase respon-
sible for G6P transport across the ER membrane. The gene
spans a region of approximately 4 kb and consists of nine
exons. Exon 7 is a small exon of 66 nucleotides that has
been very recently found to be present in brain mRNAs
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Table 3
Mutations identi¢ed in seven GSD 1b patients
Patient Glucose-6-phosphatase activity Liver
glycogen
Mutation E¡ect on the amino acid sequence Alleles involved
Untreated
microsomes
Disrupted
microsomes
3 0.15 5.3 13% 1211^1212delCT (exon 8) RFS after Ala-347. Stop codon arises
after the ¢rst 400 aa
maternal and
paternal
7 0.37 2.6 6.4% 1211^1212delCT (exon 8) RFS after Ala-347. Stop codon arises
after the ¢rst 400 aa
maternal
10 0.4 4.7 8.6% normal: AAGgtggtgagt splicing error between exons 2 and 3 maternal and
paternal
mutant: AAGgtgagt
(5P splice site of intron 2)
14 0 1.64 9.5% None found
15 ND ND ND 350delG (exon 2) RFS after Tyr-60. Stop codon arises
after the ¢rst 94 aa
parents not
available
18 ND ND ND 1094delG (exon 6) RFS after Met-308. Stop codon arises
after the ¢rst 311 aa
paternal
G1068A (exon 6) Arg300His maternal
C32 Vmax = 0 Vmax = 0.4
Km = 0.2
2025 1211^1212delCT (exon 8) RFS after Ala-347. Stop codon arises
after the ¢rst 400 aa
paternal
RFS, reading frame shift. The position of mutations is given according to the numbering of the previously published cDNA sequence [14]. Glucose-
6-phosphatase activity values for patients 3, 7, 10 and 14 are expressed in U/mg wet weight liver using 50 mM glucose-6-phosphate as substrate; for
patient C32 they are expressed as Vmax Wmoles/min/mg microsomal protein and Km mM; the data for patient C32 have been corrected for
microsomal intactness. Glycogen values are expressed as % wet weight for patients 3, 7, 10 and 14; for patient C32 they are expressed as Wg/
mg microsomal protein with the normal range being 6 800 Wg/mg microsomal protein. ND, not determined.
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whereas the mRNA present in liver is a splicing variant miss-
ing exon 7 [14,16]. The gene has been physically mapped to
human chromosome 11q23.3. This is in agreement with recent
results that have linked the GSD 1b locus to genetic markers
in the same region [17]. More recently the GSD 1c locus has
also been mapped to chromosome 11 in position q23^24.2
[28], suggesting that either the same gene is responsible for
the two subtypes or that another closely linked gene is in-
volved in GSD 1c.
On the basis of the gene structure, we set up SSCP condi-
tions to analyse DNA from seven unrelated GSD 1b patients.
The clinical symptoms of these patients were consistent with
GSD 1b [1]. The activity of the G6Pase system in liver biopsy
samples (when measured) was also consistent with classical
GSD 1b [1,6,7]. In these patients we detected ¢ve novel mu-
tations a¡ecting the coding capability of this gene. These re-
sults, together with those previously reported by van Schaf-
tingen and colleagues [14] strongly suggest that the gene does
encode the G6P transport protein(s) necessary to allow
G6Pase activity. In four patients we found mutations a¡ecting
both alleles. Analysis of parents (when available) was in agree-
ment with the expected recessive inheritance trait [1]. The
missense mutation identi¢ed (Arg300His) causes the substitu-
tion of an amino acid strictly conserved among the di¡erent
species of bacteria [14,16] analysed. All the three deletions
identi¢ed cause the synthesis of truncated proteins (Table 3)
missing the two lysines at the carboxy terminus necessary as a
retention signal in the ER membrane [29]. The described mu-
tations in this paper are likely loss of function mutations. This
is consistent with the activity data in the fresh (and intact)
liver biopsy samples, where activity was either completely ab-
sent or extremely low. SSCP analysis of the other three pa-
tients revealed mutations a¡ecting only one allele in two of
them, but no mutations in the remaining one. Since genetic
heterogeneity has not been reported in GSD 1b, it is likely
that this could be accounted by the e⁄ciency of the SSCP
method in detecting conformational variants [21], although
we cannot exclude that there could be mutations in the pro-
moter or other untranslated regions of the gene.
In conclusion, the data reported demonstrate the associa-
tion between the gene we have characterised and the GSD 1b
disease. Furthermore they also represent a useful tool for
genetic diagnostic procedure and for searching for (new) mu-
tations in GSD 1b patients.
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